Media stories about CytomX Therapeutics (NASDAQ:CTMX) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. CytomX Therapeutics earned a news impact score of 0.24 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.9189134269675 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
CytomX Therapeutics (CTMX) opened at $27.84 on Wednesday. CytomX Therapeutics has a 12 month low of $11.44 and a 12 month high of $29.04. The stock has a market cap of $1,070.00 and a P/E ratio of -17.73.
A number of research analysts recently issued reports on the stock. BidaskClub upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, February 12th. Citigroup assumed coverage on shares of CytomX Therapeutics in a research note on Friday, January 5th. They issued a “buy” rating and a $40.00 price target for the company. Finally, ValuEngine downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Three analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $32.78.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.